Loading...
Loading...
TRDA| Name | Value |
|---|---|
| Revenues | 43.7M |
| Cost of Revenue | 0.8M |
| Gross Profit | 42.9M |
| Operating Expense | 29.7M |
| Operating I/L | 14.0M |
| Other Income/Expense | 4.1M |
| Interest Income | 4.1M |
| Pretax | 18.1M |
| Income Tax Expense | -17.4M |
| Net Income/Loss | 35.5M |
Entrada Therapeutics, Inc. is a biotechnology company specializing in the development of endosomal escape vehicle (EEV) therapeutics for neuromuscular diseases. Their platform focuses on oligonucleotide, antibody, and enzyme-based programs, with lead candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1. Additionally, they are developing EEV-PMO-CAG for myotonic dystrophy type 1 treatment. The company generates revenue through the development and potential commercialization of these therapeutic programs.
